Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Laboratory Biomarker Analysis

Related Conditions

Often studied with 19 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01989572Phase 3Completed

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Showing all 1 trials

Research Network

Common Treatments

  • Laboratory Biomarker Analysis1

Active Sponsors

  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Stage Iia Uveal Melanoma Ajcc V71
  • Small Size Posterior Uveal Melanoma1
  • Stage Iib Uveal Melanoma Ajcc V71
  • Stage Iiib Uveal Melanoma Ajcc V71
  • Ocular Melanoma With Extraocular Extension1

Activity Timeline